Journal: Journal of Traditional and Complementary Medicine
Article Title: Combination therapy of Shinbaro and celecoxib improves joint pain and cartilage degradation in an osteoarthritis mouse model
doi: 10.1016/j.jtcme.2025.03.004
Figure Lengend Snippet: Fig. 7. Combined effect of Shinbaro and celecoxib on ECM components and ECM-degrading enzymes in a DMM-induced osteoarthritis model. (A–D) Representative images of immunofluorescence staining used to evaluate the expression levels of representative components of ECM. (A) COL2A1, (B) aggrecan, (C) MMP13, and (D) ADAMTS5 in the medial tibial plateau of mice after 8 weeks of oral administration. The staining shows COL2A1 in red, aggrecan in green, MMP13 in green, ADAMTS5 in green, and nuclei in blue (DAPI). Scale bar: 50 μm. (E–H) Optical density analysis of the medial tibial plateau performed to quantify the expression of (E) COL2A1, (F) aggrecan, (G) MMP13, and (H) ADAMTS5. N = 5/group. *p < 0.05, **p < 0.01, ***p < 0.001 vs. Sham; #p < 0.05, ##p < 0.01 vs. DMM. Data were analyzed using one-way ANOVA followed by Tukey’s post hoc test and are presented as mean ± SD. DMM + Shin, DMM + Shinbaro (100 mg/kg); DMM + Cel15, DMM + celecoxib (15 mg/kg); DMM + Cel30, DMM + celecoxib (30 mg/kg); DMM + Shin + Cel15, DMM + Shinbaro (100 mg/kg) + celecoxib (15 mg/kg). COL2A1, type II collagen; MMP13, matrix metallopeptidase 13; ADAMTS5, a disintegrin and metalloproteinase with thrombospondin motifs 5.
Article Snippet: Primary antibodies against COL2A1 (mouse, 1:100, sc-52658; Santa Cruz Biotechnology Inc.), aggrecan (rabbit, 1:2000, AB313636; Abcam), MMP13 (rabbit, 1:100, 18165-1-AP; Proteintech), and ADAMTS5 (rabbit, 1:200, NBP215286; Novus Biologicals) were diluted in 1 × PBST (PBS + 0.3 % Triton X-100) supplemented with 0.3 % goat serum (Sigma-Aldrich).
Techniques: Immunofluorescence, Staining, Expressing